Vidac Pharma's stock has been one of the positive surprises of the past few months. Driven by strong newsflow, the share price of the cancer-focused company has more than doubled since its low at the end of May at under EUR 0.18. The current consolidation at around EUR 0.30 offers an interesting entry opportunity, as analysts see the potential for a tenfold increase. The German research firm Sphene Capital recommends the Vidac share with a price target of EUR 4.90 in the base case scenario.